Biotech startup Elastrin Therapeutics receives seed funding from KIZOO

04 March 2021
Client work

Team:

Robert Hull

On March 4, 2021, Kizoo Technology Capital ("KIZOO") of Germany announced that it had provided seed funding for Elastrin Therapeutics ("Elastrin").

Elastrin is a biotechnology startup based in South Carolina and leveraging a platform technology to develop therapeutics that render calcified tissue and organs supple again.

Robert Hull of Gowling WLG advised one of the co-founders of Elastrin with respect to the negotiation of this funding.

NOT LEGAL ADVICE. Information made available on this website in any form is for information purposes only. It is not, and should not be taken as, legal advice. You should not rely on, or take or fail to take any action based upon this information. Never disregard professional legal advice or delay in seeking legal advice because of something you have read on this website. Gowling WLG professionals will be pleased to discuss resolutions to specific legal concerns you may have.
Related   Life Sciences, Private Equity

Team

Related Insights & Resources

Client work
19 January 2021 Innodem Neurosciences closes US$6 million Series A financing round
Client work
27 August 2020 Northpond Ventures co-leads US$55 million Series A financing round for Triumvira Immunologics

Team

Download or print PDF